Lexicon Presents LX4211 Data at American Diabetes Association Meeting - 21 News Now, More Local News for Youngstown, Ohio -

Lexicon Presents LX4211 Data at American Diabetes Association Meeting

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Lexicon Pharmaceuticals, Inc.

Results from Clinical Study in Type 2 Diabetes Patients with Renal Impairment and Preclinical Study in Type 1 Diabetes

THE WOODLANDS, Texas, June 14, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), presented data at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to lower blood glucose levels through two insulin-independent mechanisms of action.  Results presented from a clinical study showed that LX4211 significantly reduced postprandial glucose levels in type 2 diabetes patients with moderate to severe renal impairment.

In a double-blind, randomized, placebo-controlled, parallel-group study with 31 patients, LX4211 provided statistically significant reductions (p=0.003) in postprandial glucose in type 2 diabetes patients with moderate to severe renal impairment.  In a sub-group analysis of patients with the most advanced renal impairment, defined as those with a glomerular filtration rate (GFR) of less than 45 ml/min/1.73 m2, LX4211 similarly reduced postprandial glucose as compared to placebo (p=0.002).  Exhibiting its inhibition of SGLT1, LX4211 produced significant elevations in both total GLP-1 (p=0.017) and active GLP-1 (p=0.042) across all patients.  There were no serious adverse events and no discontinuations due to adverse events during the study.

In an additional presentation at ADA, Lexicon presented data showing that LX4211 improved glycemic control in mice with poorly controlled type 1 diabetes.  LX4211 significantly lowered blood glucose levels in both the low dose (2 mg/kg LX4211) and high dose (30 mg/kg LX4211) groups while reducing the occurrences of hypoglycemia.  In addition, LX4211 significantly slowed the rise in HbA1c levels as compared to vehicle-treated mice with poorly controlled type 1 diabetes.

Complete presentations of the data are available for download from Lexicon's corporate website www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease.  Lexicon currently has drug programs in clinical development for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

©2012 PR Newswire. All Rights Reserved.

  • More From wfmj.comMore>>

  • Toledo zoo welcomes 100-year-old tortoise

    Toledo zoo welcomes 100-year-old tortoise

    Thursday, August 28 2014 8:11 AM EDT2014-08-28 12:11:09 GMT
    TOLEDO, Ohio (AP) - The newest resident of the Toledo Zoo is a 100-year-old dome-shelled Galapagos tortoise that weighs in at 440 pounds. The tortoise, named Emerson, arrived at the zoo Wednesday night from the San Diego Zoo. He was escorted by Toledo Zoo personnel on his flight to Detroit before being driven to Toledo and uncrated inside a heated shed. Handlers welcomed him with carrot and sweet potato treats and a neck rub. The (Toledo) Blade reports Emerson is the zoo's first Galapagos to...More >>
    TOLEDO, Ohio (AP) - The newest resident of the Toledo Zoo is a 100-year-old dome-shelled Galapagos tortoise that weighs in at 440 pounds. The tortoise, named Emerson, arrived at the zoo Wednesday night from the San Diego Zoo. He was escorted by Toledo Zoo personnel on his flight to Detroit before being driven to Toledo and uncrated inside a heated shed. Handlers welcomed him with carrot and sweet potato treats and a neck rub. The (Toledo) Blade reports Emerson is the zoo's first Galapagos to...More >>
  • Ohio serial rapist gets 135 years in prison

    Ohio serial rapist gets 135 years in prison

    Thursday, August 28 2014 8:10 AM EDT2014-08-28 12:10:21 GMT
    CLEVELAND (AP) - A man who was linked to seven Cleveland-area rapes when authorities reopened hundreds of previously unsolved rape cases has been sentenced to up to 135 years in prison. The sentence by a judge in Cuyahoga County on Wednesday means 69-year-old Robert Green likely will never get out of prison. He was indicted in five of the cases in November and two more in May. He pleaded guilty. The (Cleveland) Plain Dealer reports that the rapes occurred over nearly a decade. They were unso...More >>
    CLEVELAND (AP) - A man who was linked to seven Cleveland-area rapes when authorities reopened hundreds of previously unsolved rape cases has been sentenced to up to 135 years in prison. The sentence by a judge in Cuyahoga County on Wednesday means 69-year-old Robert Green likely will never get out of prison. He was indicted in five of the cases in November and two more in May. He pleaded guilty. The (Cleveland) Plain Dealer reports that the rapes occurred over nearly a decade. They were unso...More >>
  • Drone delays landing of Ohio hospital chopper

    Drone delays landing of Ohio hospital chopper

    Thursday, August 28 2014 8:08 AM EDT2014-08-28 12:08:46 GMT
    DAYTON, Ohio (AP) - Officials at a southwest Ohio hospital say a drone flying near the building delayed the landing of an emergency medical helicopter for nine minutes. The health of the patient aboard the helicopter trying to land at Miami Valley Hospital in Dayton wasn't compromised, but an official says the man flying the drone violated an FAA guideline that the operator must be at least 400 feet away from a hospital. Dayton Daily News reports that the Monday incident highlights the need ...More >>
    DAYTON, Ohio (AP) - Officials at a southwest Ohio hospital say a drone flying near the building delayed the landing of an emergency medical helicopter for nine minutes. The health of the patient aboard the helicopter trying to land at Miami Valley Hospital in Dayton wasn't compromised, but an official says the man flying the drone violated an FAA guideline that the operator must be at least 400 feet away from a hospital. Dayton Daily News reports that the Monday incident highlights the need ...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms